EVO301 Subcutaneous / Evommune - LARVOL DELTA

EVO301 – Injectable IL-18 Binding Protein Fusion Protein Program (Businesswire) - "Full Results from Positive Phase 2a Trial in AD to be Presented at Upcoming Medical Conference...Phase 2b AD Trial to Initiate in mid-2027: The planned Phase 2b, placebo-controlled, dose-ranging clinical trial is expected to include at least three subcutaneous dosing regimens of EVO301 tested over a 16-week treatment period."

New P2b trial • P2a data • Atopic Dermatitis • Immunology

AprilBio to pitch REMAP platform at BIO 2026 as licensed assets show clinical progress (Korea Biomedical Review) - "Evommune is expected to present the full phase 2a results at the European Academy of Dermatology and Venereology (EADV) Congress in September. The company is also expected to pursue further development, including transitioning to a subcutaneous formulation and optimizing doses in later-stage trials."

P2a data • Pipeline update • Atopic Dermatitis • Immunology

EVO301 – Injectable IL-18 Binding Protein Fusion Protein (Yahoo Finance UK) - "Evommune has completed work on a high-concentration subcutaneous formulation of EVO301 and manufacturing has been initiated...The planned Phase 2b, placebo-controlled, dose-ranging clinical trial is expected to include at least three dosing regimens of EVO301 tested over a 16-week treatment period, with a planned trial start in mid-2027 following completion of standard scale-up and toxicology activities...The Company continues to evaluate additional indications for EVO301, including ulcerative colitis, certain cardiovascular-related inflammatory conditions and food allergy, as potential new Phase 2 clinical trials....Upcoming Preclinical Data Presentation at Society for Investigative Dermatology (SID) 2026 Annual Meeting."

Commercial • New P2b trial • Preclinical • Allergy • Atopic Dermatitis • Cardiovascular • Ulcerative Colitis